We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

390 hedge funds and large institutions have $3.64B invested in Takeda Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 308 funds opening new positions, 62 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,322% more first-time investments, than exits

New positions opened: 308 | Existing positions closed: 9

1,500% more funds holding in top 10

Funds holding in top 10: 1 → 16 (+15)

343% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 14

319% more funds holding

Funds holding: 93 → 390 (+297)

300% more capital invested

Capital invested by funds: $910M → $3.64B (+$2.73B)

4.64% more ownership

Funds ownership: 6.8% → 11.43% (+4.6%)

1% less call options, than puts

Call options by funds: $94.4M | Put options by funds: $95.5M

Holders
390
Holders Change
+297
Holders Change %
+319.35%
% of All Funds
8.44%
Holding in Top 10
16
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+1,500%
% of All Funds
0.35%
New
308
Increased
62
Reduced
14
Closed
9
Calls
$94.4M
Puts
$95.5M
Net Calls
-$1.07M
Net Calls Change
-$4.21M

Top Buyers

Rank Fund Capital Flow
1
GCM
Glenview Capital Management
New York
+$525M
2
PC
Paulson & Co
New York
+$267M
3
BG
Baupost Group
Massachusetts
+$215M
4
AC
Adelphi Capital
United Kingdom
+$187M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$152M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$200M
2
Citigroup
Citigroup
New York
-$127M
3
Bank of America
Bank of America
North Carolina
-$90.5M
4
Goldman Sachs
Goldman Sachs
New York
-$47.1M
5
CS
Credit Suisse
Switzerland
-$23.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
CFB
226
Cullen/Frost Bankers
Texas
$128K +$126K +6,282 New
AIM
227
Advantage Investment Management
Iowa
$121K +$119K +5,931 New
PI
228
PEAK6 Investments
Illinois
$113K +$112K +5,567 New
CCA
229
Catalyst Capital Advisors
New York
$92K +$91K +4,522 New
IDBONY
230
Israel Discount Bank of New York
New York
$91K +$90.1K +4,479 New
Schroder Investment Management Group
231
Schroder Investment Management Group
United Kingdom
$87K +$85.8K +4,264 New
TJHA
232
Thomas J. Herzfeld Advisors
Florida
$81K – – –
VRM
233
Vectors Research Management
New York
$80K +$79.5K +3,951 New
WCM
234
Whitener Capital Management
North Carolina
$78K +$77.2K +3,837 New
ST
235
Smithfield Trust
Pennsylvania
$76K +$74.9K +3,723 New
GRP
236
Global Retirement Partners
California
$70K +$26.7K +1,326 +63%
VFA
237
Valeo Financial Advisors
Indiana
$66K +$64.8K +3,222 New
WT
238
Whittier Trust
California
$65K +$64.1K +3,187 New
VCM
239
Vigilant Capital Management
Maine
$63K +$61.8K +3,070 New
RCC
240
Red Cedar Capital
Nebraska
$62K +$61.5K +3,054 New
JWA
241
JFS Wealth Advisors
Pennsylvania
$59K +$6.96K +346 +14%
ZB
242
Zions Bancorporation
Utah
$57K +$56K +2,784 New
TAIM
243
TD Ameritrade Investment Management
Nebraska
$56K +$865 +43 +2%
EWM
244
Edge Wealth Management
New York
$55K +$54.7K +2,716 New
FDCDDQ
245
Federation des caisses Desjardins du Quebec
Quebec, Canada
$54K +$53.3K +2,649 New
SWM
246
SeaCrest Wealth Management
New York
$53K +$52K +2,582 +6,621%
SAM
247
Sycomore Asset Management
France
$51K +$50.6K +2,517 New
CCM
248
Covington Capital Management
California
$48K +$47K +2,335 New
CAW
249
Cornerstone Advisors (Washington)
Washington
$46K +$39.1K +1,944 +596%
SCM
250
Shelton Capital Management
Colorado
$45.7K +$18.8K +932 New
8 9
10
11 12

TAK Hedge Fund Activity: Q1 2019 in Review

390 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2019, worth a combined $3.64B — up 300% from $910M a quarter earlier.

Buyers outnumbered sellers: 308 funds opened new TAK positions and 9 closed out — a net gain of 299 holders — while 62 added to existing stakes and 14 trimmed.

The largest buyer was Glenview Capital Management, opening a new position worth an estimated $525M. The largest seller was UBS Group, cutting an estimated $200M.

  • 390 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2019, up from 93 in Q4 2018.
  • Funds reported $3.64B of Takeda Pharmaceutical stock for Q1 2019, up 300% quarter-over-quarter.
  • 308 funds opened new Takeda Pharmaceutical positions in Q1 2019 and 9 closed out, a net change of +299 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2019 was Glenview Capital Management, an estimated $525M added.
  • The largest Takeda Pharmaceutical seller in Q1 2019 was UBS Group, an estimated $200M sold.

Based on aggregated 13F filings for Q1 2019.